|
|
 |
|
Viewing report
|
|
|
|
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Datamonitor, Nov 2008
Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical companies, the pressure to meet this need and maintain market share is growing as the patent expiries of three major brands draws near.
Scope
- Analysis of key marketed brands and late-stage pipeline drugs.
- Anxiety disorders-specific drug sales volume and value forecasts to 2017 in the US, Japan, and five major European markets.
- Identification of future market events that are expected to affect anxiety disorders drug revenues.
- Analysis of patient potential, unmet needs and clinical trial design in anxiety disorder.
Highlights of this title
Atypical antipsychotics are expected to change the landscape of the future anxiety disorders market, with Seroquel XR set to benefit from first-to-market status upon approval in generalized anxiety disorder. Seroquel XR will be positioned as a second/third-line treatment for patients who have failed to respond to available antidepressants.
In view of the high co-morbidity between anxiety and depression, it remains in the interests of antidepressant manufacturers to maximize the patient potential of their products. However, with three key brands set to experience patent expiration over the forecast period (20082017), competition within the antidepressant drug classes will intensify.
The presence of neurokinin (NK) receptor antagonists and corticotrophin releasing factor (CRF) antagonists in the anxiety disorders pipeline have generated much interest among interviewed key opinion leaders. Datamonitor regards NK receptor antagonists as holding the greatest promise in the treatment of anxiety disorders.
Key reasons to purchase this title
- Understand the current anxiety disorder market dynamics and how they are expected to evolve out to 2017.
- Benchmark key late-stage pipeline anxiety disorder compounds against the current market leading brands.
- Understand unmet needs in the anxiety disorders market based on key opinion leader comments.
Customers who bought this item also bought
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Anxiety Disorders - A Decade of Declining Revenues
Strategic Perspectives 2001: Generalized Anxiety Disorder - Driven by Effexor and Open to Expansion
Anxiety, Phobias & Panic Disorders - 2009 Edition
Stakeholder Insight: Anxiety Disorders - More Than Just a Comorbidity
Strategic Perspectives 2001: Social Anxiety Disorder - The Target Anxiety Market For Leading Players
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
R&D Update: What's on the Horizon for the Panic Disorder Market?
Thought Leader Insight & Analysis: Anxiety & Depression
Strategic Perspectives: CNS Disorders in Women - Premenstrual Syndrome/Premenstrual Dysphoric Disorder
Strategic Perspectives 2001: Panic Disorder - Opportunities For Antidepressant Expansion
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
|
|
|
|
